F8 and von Willebrand disease 3: T‐TAS could be of added value in monitoring patients receiving VWF‐FVIII treatment as one study suggests that the AR‐chip was able to assess the differences in coagulation‐dependent thrombus formation in VWD Type 3 patients, before and after administration of VWF‐FVIII treatment.